The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management

Journal of Clinical Oncology

Volumn 22, Issue 11, 2004, Pages 2141-2149

  Cooperberg, Matthew R ^a   Lubeck, Deborah P ^a   Meng, Maxwell V ^a   Mehta, Shilpa S ^a   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; AGED; BLOOD; DECISION MAKING; DISEASE COURSE; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PROSTATE TUMOR; RISK ASSESSMENT; RISK FACTOR; SOCIOECONOMICS; UNITED STATES;

AGED; AGED, 80 AND OVER; DECISION MAKING; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; SOCIOECONOMIC FACTORS; STATISTICS, NONPARAMETRIC; UNITED STATES;

EID: 2942677245     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.062     Document Type: Article

References (43)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003
2. Quinlan DM, Partin AW, Walsh PC: Can aggressive prostatic carcinomas be identified and can their natural history be altered by treatment? Urology 46:77-82, 1995
3. Steinberg GD, Bales GT, Brendler CB: An analysis of watchful waiting for clinically localized prostate cancer. J Urol 159:1431-1436, 1998
4. Etzioni R, Penson DF, Legler JM, et al: Overdiagnosis due to prostate-specific antigen screening: Lessons from U. S. prostate cancer incidence trends. J Natl Cancer Inst 94:981-990, 2002
5. Han M, Partin AW, Zahurak M, et al: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-523, 2003
6. Roach M, Lu J, Pilepich MV, et al: Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47:609-615, 2000
7. Schellhammer PF, Moriarty R, Bostwick D, et al: Fifteen-year minimum follow-up of a prostate brachytherapy series: Comparing the past with the present. Urology 56:436-439, 2000
8. Holmberg L, Bill-Axelson A, Helgesen F, et al: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347:781-789, 2002
9. Wei JT, Dunn RL, Sandler HM, et al: Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20:557-566, 2002
10. Carter HB, Walsh PC, Landis P, et al: Expectant management of nonpalpable prostate cancer with curative intent: Preliminary results. J Urol 167:1231-1234, 2002
11. Choo R, Klotz L, Danjoux C, et al: Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167:1664-1669, 2002
12. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
13. D'Amico AV: Combined-modality staging in predicting prostate-specific antigen outcome after definitive local therapy for men with clinically localized prostate cancer, in D'Amico AV (ed): Prostate Cancer: Principles and Practice. Philadelphia, PA, Lippincott Williams & Wilkins, 2002, pp 254-268
14. Lubeck DP, Litwin MS, Henning JM, et al: The CaPSURE database: A methodology for clinical practice and research in prostate cancer-CaPSURE Research Panel: Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 48:773-777, 1996
15. Cooperberg MR, Broering JM, Litwin MS, et al: The contemporary management of prostate cancer in the United States: Lessons from CaPSURE, a national disease registry. J Urol 171:1393-1401, 2004
16. Harlan LC, Potosky A, Gilliland FD, et al: Factors associated with initial therapy for clinically localized prostate cancer: Prostate cancer outcomes study. J Natl Cancer Inst 93:1864-1871, 2001
17. Alibhai SMH, Naglie G, Nam R, et al: Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol 21:3318-3327, 2003
18. McGregor M, Hanley JA, Boivin JF, et al: Screening for prostate cancer: Estimating the magnitude of overdetection. CMAJ 159:1368-1372, 1998
19. Hugosson J, Aus G, Becker C, et al: Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int 85:1078-1084, 2000
20. Kattan MW, Eastham JA, Stapleton AM, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766-771, 1998
21. Cooperberg MR, Lubeck DP, Mehta SS, et al: Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE). J Urol 170:521-527, 2003
22. Smith EB, Frierson HF Jr, Mills SE, et al: Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: Is there evidence for systematic upgrading? Cancer 94:2282-2287, 2002
23. Meigs JB, Barry MJ, Giovannucci E, et al: High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia. Am J Med 104:517-525, 1998
24. American Urological Association Prostate Cancer Clinical Guidelines Panel: Report on the management of clinically localized prostate cancer. Baltimore, MD, American Urological Association Inc, 1995
25. Labrie F, Cusan L, Gomez JL, et al: Long-term combined androgen blockade alone for localized prostate cancer. Mol Urol 3:217-226, 1999
26. Akaza H, Homma Y, Okada K, et al: Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: A prospective and randomized study-The Prostate Cancer Study Group. Jpn J Clin Oncol 30:131-136, 2000
27. Leibowitz RL, Tucker SJ: Treatment of localized prostate cancer with intermittent triple androgen blockade: Preliminary results in 110 consecutive patients. Oncologist 6:177-182, 2001
28. The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer-Initial results of the Medical Research Council Trial. Br J Urol 79:235-246, 1997
29. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
30. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15:1013-1021, 1997
31. Powell IJ, Tangen CM, Miller GJ, et al: Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year follow-up-Phase II Southwest Oncology Group Study 9109. J Urol 168:2016-2019, 2002
32. Soloway MS, Pareek K, Sharifi R, et al: Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. J Urol 167:112-116, 2002
33. Aus G, Abrahamsson PA, Ahlgren G, et al: Three-month neoadjuvant hormonal therapy before radical prostatectomy: A 7-year follow-up of a randomized controlled trial. BJU Int 90:561-566, 2002
34. Potters L, Torre T, Ashley R, et al: Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 18:1187-1192, 2000
35. Penson DF, Schonfeld WH, Flanders SC, et al: Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: Results from the CaPSURE database. Urology 57:499-503, 2001
36. Chodak GW, Keane T, Klotz L: Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 60:201-208, 2002
37. Nilsson-Ehle H, Jagenburg R, Landahl S, et al: Blood haemoglobin declines in the elderly: Implications for reference intervals from age 70 to 88. Eur J Haematol 65:297-305, 2000
38. Roy DK, O'Neill TW, Finn JD, et al: Determinants of incident vertebral fracture in men and women: Results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 14: 19-26, 2003
39. Kurek R, Renneberg H, Lubben G, et al: Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 35:27-31, 1999 (suppl 1)
40. Alibhai SMH, Krahn MD, Cohen MM, et al: Is there age bias in the treatment of localized prostate carcinoma? Cancer 100:71-81, 2003
41. Hugosson J, Aus G, Bergdahl C, et al: Prostate cancer mortality in patients surviving more than 10 years after diagnosis. J Urol 154: 2115-2117, 1995
42. Brasso K, Friis S, Juel K, et al: Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: A population based registry study. J Urol 161:524-528, 1999
43. O'Leary MP, Baum NH, Blizzard R, et al: 2001 American Urological Association Gallup Survey: Changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction. J Urol 168: 649-652, 2002